<DOC>
	<DOCNO>NCT01265654</DOCNO>
	<brief_summary>Breast cancer lead type cancer woman . Although big advance diagnostics treatment early breast cancer make recent year breast cancer still significant mortality rate . A number treatment modality exist postmenopausal woman advance breast cancer . The treatment modality choose base patient tumour characteristic . Hormonal treatment prefer recommended woman hormone sensitive breast cancer ( ESMO , CECOG NCCN guideline ) . Tumor marker establish method monitoring systemic therapy various cancer . Tumor marker CA 15-3 CEA use clinical practice monitor treatment efficacy metastatic breast cancer . Blood level tumor marker widely use assess response/progression treatment guide therapy change . Treatment efficacy assess image method clinical study . Change therapy clinical study usually do progression base RECIST criterion find . Hormonal treatment slower onset effect compare chemotherapy last several week . Also new therapy start spurious early rise may occur . Therefore rise level tumor marker first week new hormonal therapy necessarily sign progression guidance treatment change . Evidence treatment efficacy form clinical study treatment change base image technique .</brief_summary>
	<brief_title>Reasons Changing HOrmonal Therapy Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Women least two finished line hormonal treatment advance breast cancer Tumor marker ( CEA . CA153 ) value available time onset discontinuation therapy Imaging method result available time onset discontinuation therapy</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Advanced Breast Cancer</keyword>
	<keyword>Hormonal Treatment</keyword>
</DOC>